HLS Therapeutics Inc. (TSE:HLS) Declares Quarterly Dividend of $0.05

HLS Therapeutics Inc. (TSE:HLS – Get Rating) declared a quarterly dividend on Wednesday, March 15th, Zacks reports. Stockholders of record on Friday, April 28th will be given a dividend of 0.05 per share on Thursday, June 15th. This represents a $0.20 annualized dividend and a dividend yield of 2.79%. The ex-dividend date of this dividend is Thursday, April 27th.

HLS Therapeutics Stock Down 16.0 %

HLS Therapeutics stock opened at C$7.18 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.46 and a debt-to-equity ratio of 75.85. The company has a market capitalization of C$232.49 million, a PE ratio of -7.72 and a beta of 0.86. The firm’s fifty day moving average is C$9.08 and its 200 day moving average is C$9.48. HLS Therapeutics has a 12-month low of C$6.79 and a 12-month high of C$15.59.

HLS Therapeutics Company Profile

(Get Rating)

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.